Physician profile
James P Gavin
NPI 1609875491
$103,367.75
in general payments reported to CMS, 2019-2025
16 companies · $15K in 2025
The $15K reported for 2025 was more than what 96% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $15K · 2020: $5,440 · 2021: $7,180 · 2022: $32K · 2023: $21K · 2024: $7,836 · 2025: $15K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $32K · Travel and Lodging: $9,601 · Food and Beverage: $2,451 · Education: $7.47.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $31,549.00 |
| Travel and Lodging | $9,601.13 |
| Food and Beverage | $2,450.65 |
| Education | $7.47 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $65,977.38 | 2019-2025 | Freestyle Libre 3, Freestyle Libre, Freestyle Libre 2 |
| Lilly USA, LLC | $25,595.17 | 2022 | |
| Embecta Corp. | $6,419.00 | 2023 | |
| Eli Lilly and Company | $3,418.86 | 2022 | |
| Xeris Pharmaceuticals, INC. | $699.00 | 2023 | Gvoke Hypopen |
| Intuity Medical INC | $500.00 | 2022 | |
| Amgen INC. | $188.12 | 2019 | |
| Travere Therapeutics, INC. | $132.47 | 2023-2024 | |
| Corcept Therapeutics | $125.39 | 2025 | Korlym |
| Astrazeneca Pharmaceuticals LP | $106.66 | 2019-2023 | Farxiga |
| Otsuka America Pharmaceutical, INC. | $64.42 | 2019-2024 | Jynarque |
| Akebia Therapeutics INC | $37.81 | 2019 | |
| Ardelyx, INC. | $34.79 | 2024-2025 | Ibsrela |
| Alexion Pharmaceuticals, INC. | $25.52 | 2019 | |
| Aurinia Pharma U.S., INC. | $24.21 | 2024 | Lupkynis |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Fresenius USA Marketing, INC. | $18.95 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Gavin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.